S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
ETR:MOR

MorphoSys - MOR Stock Forecast, Price & News

€19.32
+0.88 (+4.77%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
€18.50
€19.77
50-Day Range
€12.05
€18.38
52-Week Range
€13.90
€36.02
Volume
192,276 shs
Average Volume
153,687 shs
Market Capitalization
$660.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
€24.92
MOR stock logo

About MorphoSys (ETR:MOR) Stock

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

MOR Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
MorphoSys AG (NASDAQ:MOR) Q3 2022 Earnings Call Transcript
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
MorphoSys CFO Sung Lee To Step Down In March 2023
MorphoSys AG: Financial Calendar 2023
European ADRs Climb in Tuesday Trading
See More Headlines
Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
732
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
€24.92
High Stock Price Forecast
€65.00
Low Stock Price Forecast
€11.00
Forecasted Upside/Downside
+28.9%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$249.61 million
Cash Flow
€37.28 per share
Book Value
(€2.52) per share

Miscellaneous

Free Float
N/A
Market Cap
$660.16 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Jean-Paul Kress M.D. (Age 57)
    Chairman of Management Board, MD & CEO
    Comp: $1.94M
  • Mr. Sung H. Lee (Age 52)
    CFO & Member of Management Board
    Comp: $488.7k
  • Dr. Malte Peters M.D. (Age 60)
    Exec. Officer
    Comp: $1.15M
  • Dr. Marlies Sproll (Age 64)
    Special Adviser to the Chief Exec. Officer
  • Mr. Klaus De Wall
    Head of Accounting & Tax
  • Ms. Lara Smith Weber
    Head of Controlling, Corp. Fin. & Corp. Devel.
  • Dr. Margit Urban
    Head of Discovery Alliances & Technologies
  • Dr. Anja Pomrehn
    Sr. VP & Head of Investor Relations
  • Ms. Charlotte Lohmann (Age 52)
    Sr. VP of Legal, Compliance & IP and Gen. Counsel
  • Mr. Thomas Biegi
    VP & Head of Corp. Communications













MOR Stock - Frequently Asked Questions

What is MorphoSys' stock price forecast for 2023?

0 brokerages have issued 1-year price targets for MorphoSys' shares. Their MOR share price forecasts range from €11.00 to €65.00. On average, they predict the company's stock price to reach €24.92 in the next twelve months. This suggests a possible upside of 35.1% from the stock's current price.
View analysts price targets for MOR
or view top-rated stocks among Wall Street analysts.

How have MOR shares performed in 2023?

MorphoSys' stock was trading at €13.21 at the start of the year. Since then, MOR shares have increased by 39.6% and is now trading at €18.45.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of MorphoSys own?
What is MorphoSys' stock symbol?

MorphoSys trades on the ETR under the ticker symbol "MOR."

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately €18.45.

How much money does MorphoSys make?

MorphoSys (ETR:MOR) has a market capitalization of $630.09 million and generates $249.61 million in revenue each year.

How many employees does MorphoSys have?

The company employs 732 workers across the globe.

How can I contact MorphoSys?

MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The official website for the company is www.morphosys.de. The company can be reached via phone at +49-89-899270.

This page (ETR:MOR) was last updated on 2/3/2023 by MarketBeat.com Staff